Atreca, Inc (BCEL)

Etorro trading 970x250

About Atreca, Inc

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Address: 450 East Jamie Court, South San Francisco, CA, United States, 94080

Atreca, Inc News and around…

Latest news about Atreca, Inc (BCEL) common stock and company :

How Much Of Atreca, Inc. (NASDAQ:BCEL) Do Institutions Own?
18 Nov, 2021 Yahoo! Finance

The big shareholder groups in Atreca, Inc. ( NASDAQ:BCEL ) have power over the company. Large companies usually have...

Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
02 Nov, 2021 Yahoo! Finance

SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments. "In the third quarter, we continued to advance our lead program, ATRC-101, following the re

64 Biggest Movers From Yesterday
02 Nov, 2021 FinancialContent

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock ...

12 Health Care Stocks Moving In Monday's After-Market Session
01 Nov, 2021 FinancialContent

Gainers Biophytis (NASDAQ:BPTS) shares moved upwards by 37.54% to $8.5 during Monday's after-market session. The market value of ...

12 Health Care Stocks Moving In Monday's Intraday Session
01 Nov, 2021 FinancialContent

Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's regular session. As ...

40 Stocks Moving In Monday's Mid-Day Session
01 Nov, 2021 FinancialContent

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased ...

Why Owning Six Flags Stock Should Become More Entertaining
29 Oct, 2021 Yahoo! Finance

The theme-park operator is well on its way toward full recovery from the slump caused by Covid. Also, Wall Street views on Triumph Bancorp, Coinbase Global, Beyond Meat, CACI International, and Atreca.

Hedge Funds Are Piling Into Atreca, Inc. (BCEL)
26 Oct, 2021 Yahoo! Finance

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

Cancer drug developer, Gates Foundation plot next attack on malaria
22 Oct, 2021 Yahoo! Finance

With technology licensed from Stanford, the partners hope to land a preventive drug into clinical trials against malaria by early 2023.

12 Health Care Stocks Moving In Thursday's After-Market Session
21 Oct, 2021 FinancialContent

Gainers T2 Biosystems (NASDAQ:TTOO) shares increased by 23.47% to $1.02 during Thursday's after-market session. T2 Biosystems's ...

Atreca Ink Licensing Pact With Gates Research On Malaria Antibody
21 Oct, 2021 FinancialContent

Atreca Inc(NASDAQ: BCEL) hasentered into a licensing agreementwith the Bill & Melinda Gates Medical Research ...

Atreca Inks Licensing Pact With Gates Research On Malaria Antibody
21 Oct, 2021 Yahoo! Finance

Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria. MAM01/ATRC-501 is a monoclonal antibody entering preclinical development. Under the agreement, Gates MRI will lead the development of MAM01/ATRC-501 and receive commercial rights in GAVI-eligible countries. Atreca will retain commercial rights in the U.S., Europe, and parts of Asia. MAM01/ATRC-501 is an engineered version of a hum

Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria
21 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute (the “Institute” or “Gates MRI”) to develop MAM01/ATRC-501, a novel monoclonal antibody entering precl

Relative Strength Alert For Atreca
18 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Sum Up The Pieces: PBSM Could Be Worth $46
13 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.46 per unit.

Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting, which is being held November 10-14, 2021 in Washington, D.C. Details are as follows: Title: First-in-Human Results with the Novel Tumor-Targeting An

12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Sep, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 30.57% to $30.02 during Wednesday's after-market session. Today's trading ...

Atreca to Present at Upcoming Virtual Investor Conferences
08 Sep, 2021 FinancialContent
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
11 Aug, 2021 FinancialContent
We're Not Very Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate
11 Aug, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

How The Pieces Add Up: VHT Targets $283
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $283.00 per unit.

Stocks That Hit 52-Week Lows On Friday
30 Jul, 2021 FinancialContent

On Friday morning, 33 companies hit new 52-week lows. Areas of Significance: The largest company in terms ...

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
30 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook
30 Jul, 2021 Yahoo! Finance

View more earnings on BVSSee more from BenzingaClick here for options trades from BenzingaIcosavax Kicks Off NASDAQ Debut; Trading Almost 150% Higher On IPO Price Of Atreca Stock Selloff Triggered By Interim ATRC-101 Data Appears Overdone, Stifel Says© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

70 Biggest Movers From Yesterday
30 Jul, 2021 FinancialContent

Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently ...

Were Hedge Funds Right About Atreca, Inc. (BCEL)?
29 Jul, 2021 Yahoo! Finance

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31st. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

12 Health Care Stocks Moving In Thursday's Intraday Session
29 Jul, 2021 FinancialContent

Gainers NanoVibronix (NASDAQ:NAOV) shares moved upwards by 38.21% to $2.64 during Thursday's regular session. Trading volume for ...

Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet
29 Jul, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, ...

44 Stocks Moving In Thursday's Mid-Day Session
29 Jul, 2021 FinancialContent

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration ...

Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
29 Jul, 2021 FinancialContent

Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also ...

Atreca, Inc (BCEL) is a NASDAQ Common Stock listed in , ,

970x250